India, June 2 -- Pfizer has announced the launch of a new therapy, a BCMA (B-Cell Maturation Antigen) directed bi-specific antibody in India for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).

The new medication, for those who have received 4 prior therapies, delivers a clinically meaningful improvement in progression-free survival (PFS) and a durable response for RRMM Patients, while maintaining an established safety profile.

Elranatamab is now available in India as a ready-to-use, convenient fixed-dose subcutaneous injection. It offers the option of weekly administration, followed by every-other-week dosing for patients who respond after 24 weeks of weekly treatment. Subcutaneous administration res...